Angiotensin-converting enzyme inhibitor–associated angioedema treated with C1-esterase inhibitor: A case report and review of the literature

Davis Lynn Erickson, M.D., and Christopher Albert Coop, M.D.

ABSTRACT

Case Report: A 59-year-old man currently on >5 years of angiotensin-converting enzyme inhibitor (ACEI) therapy presented to the emergency department with angioedema of the tongue and difficulty swallowing. After receiving conventional therapy of antihistamine, steroids, and epinephrine, the patient’s condition continued to deteriorate, with imminent intubation. The patient was treated with a C1-esterase inhibitor (C1-INH) and experienced rapid resolution of symptoms, which avoided airway complications.

Discussion: Although no therapy has been approved for the treatment of ACEI–associated angioedema (AAE), the conventional therapy (antihistamine, steroids, and epinephrine) often proves ineffective in this bradykinin-mediated angioedema. There are drugs approved and used for hereditary angioedema that may be effective in the acute phase of ACEI-AAE that may prevent the need for further interventions, such as intubation and tracheotomy. These drugs include icatibant, ecallantide, fresh frozen plasma, and C1-INH.

Conclusion: The literature and clinical evidence indicate C1-INH can be effectively used in the treatment of ACEI-AAE to halt the progression of the condition, prevent airway compromise and the need for intervention, and lead to rapid resolution of symptoms.

(Allergy Rhinol 7:e168–e171, 2016; doi: 10.2500/ar.2016.7.0166)
\( \mu g \text{ IV (normally dosed intramuscularly; however, he} \) \\
was given an IV because IV access was already ob-

ained) without improvement in symptoms. Fifteen 

minutes after the initial treatment; the patient received 
an additional 9 \( \mu g \) of epinephrine IV without response. 

Thirty-five minutes after treatment was initiated, the 

patient’s condition continued to decline, and airway 
collapse was imminent. The patient was dosed with 

ranitidine 150 mg IV and C1-INH (Berinert [CSL Beh-

ring GmbH, Marburg, Germany], 3000 U, 20 U/kg IV). 

A response was noted 15 minutes after the dose of the 

C1-INH, with reduction of swelling and resolution of 
dysphagia. The patient was admitted to the medical 

intensive care unit for observation overnight and for 
evaluation by an otolaryngology specialist. The pa-

tient’s complement levels were drawn and revealed no 

abnormalities in C4 level (35 mg/dL) and C1-INH 

functionality (105% mean normal).

The diagnosis of ACEI-AAE was confirmed based on 
his history, patient profile, and normal complement 

levels and functionality. The patient was discharged 

the following day without complication, with a sched-

uled follow-up with the allergy department. At the 
time of diagnosis of ACEI-AAE, the patient was in-

structed to discontinue and avoid future use of all 

ACEIs. He was transitioned to valsartan/hydrochlo-

rothiazide (160 mg/25 mg) for blood pressure control. 

At 1-year follow-up, the patient remained without re-
currence of angioedema, and his blood pressure re-
mained well controlled on the combination medica-

tion.

**DISCUSSION**

This patient’s presentation is not uncommon. Over-

all, the risk of developing ACEI-AAE is relatively low, 
at 0.1 to 0.7% of recipients. \(^1\)–\(^3\) However, given the large 

number of people (35–40 million individuals in 2001) \(^4\) 
in the United States who take an ACEI for various indica-

tions (i.e., hypertension, myocardial infarction, 

heart failure with systolic dysfunction, diabetes, and 

chronic kidney disease), \(^5\) ACEI-AAE is the leading 

cause of drug-induced angioedema in the United States. It accounts for 25 to 40% of all emergency de-

partment visits for angioedema each year. \(^4\) 

The time frame for the presentation of ACEI-AAE 
varies widely. ACEI-AAE may occur at any time, from 
commencing therapy to years after treatment. \(^1\)–\(^2\) In our 

case, the reaction occurred after 5 years of ACEI ther-

apy. In a large retrospective study, two-thirds of an-

gioedema episodes occurred within the first 3 months 
of therapy; \(^2\) however, there have been multiple case 

reports that documented episodes of ACEI-AAE after 
years of stable therapy, as with our patient. \(^1\)–\(^2\),\(^5\)–\(^7\) 

ACEI-AAE, as with other types of angioedema, is 
characterized as an asymmetric, nonpitting swelling of 
the subcutaneous or submucosal tissues, which most 
commonly affects nondependent areas. In ACEI-AAE, 
the typical areas of involvement include the lips, 
tongue, face, and intestines (which is often character-
bized by episodic abdominal pain). There is an absence 
of itching or urticaria in ACEI-AAE because the pres-
ence of urticaria merits suspicion of multiple other 
etiologies. \(^7\)–\(^8\) ACEI-AAE is typically episodic and often 
follows a fairly predictable time course. In the case 
described, the swelling developed over several hours, 
which is deemed typical because ACEI-AAE develops 
over minutes to hours, followed by a peak in symp-
toms, and resolution over the next 24 to 72 hours. However, complete resolution can be unpredictable 
and may take days, despite ACEI discontinuation. \(^4\)–\(^7\) 
Typically, the reported duration is 2–5 days and res-
olves spontaneously and requires no intervention.

The role of bradykinin in ACEI-AAE is well ac-
ccepted. Bradykinin is an inflammatory vasoactive pept-
id that leads to increased capillary permeability and 
acts as a potent vasodilator. ACEIs block the effects of 
the angiotensin-converting enzyme (ACE) (also known 
as kininase II), which impacts the renin-angiotensin-
aldoosterone pathway and diminishes the degradation 
of bradykinin. The liver produces angiotensinogen, 
which is converted to angiotensin I in the kidney by 
renin. Angiotensin I is metabolized in the lungs by 
ACE to produce angiotensin II. Angiotensin II causes 
vasoconstriction through stimulation of angiotensin I 
and II receptor.

Although ACE is the primary peptidase involved in the 
degradation of bradykinin (these effects are blocked 
by ACEI), angiotensin II also participates in the 
inactivation of bradykinin. \(^9\) Thus, ACEI further 
leads to increased levels of bradykinin by decreasing 
the production of angiotensin II. This leads to elevated 
levels of bradykinin, which also causes the release of 
nitric oxide and prostaglandins, which results in vaso-
dilatation and hypotension. \(^9\) Elevated levels of plasma 
bradykinin activity have been demonstrated in pa-

tients with ACEI angioedema. \(^10\) The high levels of 
bradykinin stimulate vasodilation and increase vascu-
lar permeability of the postcapillary venules and allow 
for plasma extravasation into the submucosal tissue, 
which leads to angioedema. \(^8\)–\(^11\) 

Although the majority of patients who take an ACEI 
will never experience ACEI-AAE, there are various risk 

factors that have been identified with an increased likelihood of such reactions. Our patient possessed risk 

factors, including African American ethnicity and daily 
aspirin use. Other risk factors to consider in patients with angioedema include the following: a history of 

previous episodes of angioedema, age >65 years, as-

pirin and other nonsteroidal anti-inflammatory use, 
female sex, smoking, seasonal allergies, mechanistic 
target of rapamycin inhibitor use, a transplantation,
and an underlying C1-inhibitor deficiency (hereditary or acquired). There seems to be a reduced risk of angioedema due to ACEIs in people with diabetes. The primary treatment of ACEI-AAE is first and foremost discontinuation of the inciting drug and management of the airway. The angioedema typically spontaneously resolves within 24–72 hours. Patients who experienced angioedema attributed to an ACEI should never resume treatment by this class of medication. In addition to discontinuation of the inciting drug and management of the airway, most angioedema attacks should be initially treated as a histamine-mediated condition because the majority of angioedema cases are histamine mediated. The treatment includes antihistamines, glucocorticoids, and epinephrine. Although these medications are the first-line treatment for angioedema, they are considered ineffective or minimally effective in treating bradykinin-mediated angioedema. In this case and multiple other reported cases, this therapy aimed at histamine-mediated angioedema was ineffective. Without any medication approved for ACEI-AAE, the next course of management is debatable yet critical when the symptoms of ACEI-AAE continue to progress and threaten the airway. There have been studies and reports that support the use of various drugs in treating bradykinin angioedema symptoms and preventing airway intubation. These drugs include synthetic bradykinin B2-receptor agonists, kallikrein inhibitors, fresh frozen plasma (FFP), and complement-1 esterase inhibitors (C1-INH).

Icatibant, a synthetic bradykinin B2-receptor antagonist, is approved for the acute treatment of HAE attacks and has been shown to be effective for the treatment of ACEI-AAE. This drug seems to be the most efficacious in the first few hours of the angioedema attack while the swelling is progressing. The efficacy of icatibant was demonstrated in a randomized trial of 27 adults who presented to the emergency department with angioedema of the upper autodigestive tract while taking an ACEI. All the subjects randomized to icatibant experienced initial relief in ~2 hours and complete resolution of angioedema in a median time of 8 hours. In comparison, those who received standard therapy (steroids, antihistamines, and epinephrine) had resolution in a median of 27.1 hours, with three patients who required rescue therapy (30 mg of icatibant and 500 mg prednisolone) and with one underwent tracheotomy.

Ecallantide (DX-88; Dyax Corp., Cambridge, MA) is a recombinant 60 amino-acid protein that specifically inhibits plasma kallikrein. This inhibition prevents the breakdown of high-molecular-weight kininogen to bradykinin, which, in turn, leads to the downregulation of high-molecular-weight kininogen (the precursor of bradykinin), which, in turn, halts the accumulation of bradykinin. Two randomized controlled trials (RCT) were performed to compare efficacy of standard therapy with ecallantide versus standard therapy with placebo, however, with mixed results. The first RCT involved 50 adults assigned to receive either ecallantide (30 mg) or placebo (in addition to standard therapy with glucocorticoids and antihistamines). The patients were required to have presented within 12 hours of symptom onset and to have worsening symptoms or failure to improve during 2 hours of initial observation. The primary end point was eligibility for discharge within 4 hours of treatment. Discharge criteria were met within 4 hours in 31 versus 21% of subjects who received ecallantide and placebo, respectively (95% confidence interval, −14 to 34%). Although the confidence intervals overlapped, which demonstrated no effect, the study did demonstrate that ecallantide is safe to use and may increase the proportion of patients who meet early discharge criteria by ~10%.

A second RCT was performed in which 76 adults with angioedema on current ACEI therapy presented for emergency care within 12 hours of symptom onset; 86% received standard therapy (glucocorticoid, antihistamine, epinephrine) and either ecallantide (at doses of 10 mg, 30 mg, or 60 mg) or placebo. The mean time from symptom onset to treatment was 7.2 hours, and 72% of patients who received placebo improved during that time. The primary end point was defined as eligibility for discharge from the emergency department within 6 hours of receiving treatment in both groups. No difference was found between the groups.

FFP (solvent detergent-treated plasma or FFP) has also been shown to be effective in various case reports. FFP works in bradykinin-mediated angioedema by supplying C1-INH and ACE to catabolize the accumulated levels of bradykinin. Case reports described administration of FFP, which led to rapid improvement of ACEI-AAE without further recurrence of symptoms. In addition, a recent retrospective cohort study demonstrated that control patients, who were not treated, were more frequently intubated in the emergency department and required more extended intensive care unit admissions (60 versus 35%, p = 0.05; 3.5 versus 1.5 days, p < 0.001, respectively).

Another option for the treatment of ACEI-AAE is the use of purified C1-INH (Berinert). C1-INH functions through the inactivation of plasma kallikrein and factor XIIa (Hageman factor), which is thought to modulate vascular permeability by preventing the generation of bradykinin, a potent mediator of vascular permeability, which, thus, counteracts the accumulation of bradykinin caused by the ACEI. This was demonstrated to be effective for ACEI-AAE in various case reports, with resolution of symptoms 20 minutes to 2
hours after dosing. However, there has not been a placebo controlled trial to prove this. One case series of 10 patients with ACEI-AAE who were treated with an average of 1000 U of C1-INH demonstrated symptom improvement at a mean time of 88 minutes and complete resolution of symptoms at 10.1 hours without the need for further interventions. This was contrasted with 47 historical patients who underwent conventional therapy (antihistamines and steroids), with a mean time of complete resolution of symptoms at 33.1 hours (three patients with tracheotomy and two who were intubated secondary to symptom progression and worsening). This improvement after C1-INH infusion was demonstrated despite underdosing the patients. Current proposed dosing is 20 U/kg (approved dose for types 1 and 2 HAE), which would have increased the average dose to 1500 U. As noted in our case, the patient was treated with 3000 U at a dosing of 20 U/kg and experienced improvement of symptoms within 15 minutes of administration.

CONCLUSION

Although the risk of ACEI-AAE is relatively low, the occurrence accounts for up to 40% of emergency department visits for angioedema. However, no drug therapy has been approved for the acute management of ACEI-AAE. The current recommended management for allergic and/or histaminergic angioedema is ineffective for bradykinin-induced angioedema and is rarely able to prevent progression of the swelling and angioedema. There are drugs used for HAE that may be effective in the acute phase of ACEI-AAE and may prevent the need for further interventions, such as intubation and tracheotomy. These drugs include icatibant, ecallantide, FFP, and C1-INH. Our case reports adds to the body of literature and clinical evidence that C1-INH may be effectively used in the treatment of ACEI-AAE to halt the progression of the condition, prevent airway compromise and the need for intervention, and lead to rapid resolution of symptoms.

REFERENCES

1. Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624–1630, 2008.
2. Toh S, Reichman ME, and Houstoun M. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 172:1582–1589, 2012.
3. Beltrami L, Zanchelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 29:2273–2277, 2011.
4. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 100:327–332, 2008.
5. Gang C, Lindsell CJ, Moellman J, et al. Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema. Allergy Asthma Proc 34:267–273, 2013.
6. Malde B, Regalado J, and Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 98:57–63, 2007.
7. Kanani A, Schellenberg R, and Warrington R. Urticaria and angioedema. Allergy Asthma Clin Immunol 7(suppl. 1):59, 2011.
8. Greve J, Bas M, Hoffmann TK, et al. Effect of C1-esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 125:E198–E202, 2015.
9. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 351:1693–1697, 1998.
10. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 10:499–509, 2004.
11. Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: Role of bradykinin. Allergy 62:842–856, 2007.
12. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: A review of the pathophysiology and risk factors. Clin Exp Allergy 40:40–61, 2010.
13. Charmillon A, Deibener J, Kaminsky P, and Louis G. Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: Successful treatment with icatibant. Intensive Care Med 40:893–894, 2014.
14. Craig TJ, Bernstein JA, Farkas H, et al. Diagnosis and treatment of bradykinin-mediated angioedema: Outcomes from an Angioedema Expert Consensus Meeting. Int Arch Allergy Immunol 165:119–127, 2014.
15. Bas M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372:418–425, 2015.
16. Bernstein JA, Moellman JJ, Collins SP, et al. Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol 114:245–249, 2015.
17. Lewis LM, Grafeeo C, Croasley P, et al. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: A multicenter, randomized, controlled trial. Ann Emerg Med 65:204–213, 2015.
18. Saeb A, Hagglund KH, and Cigolle CT. Using fresh frozen plasma for acute airway angioedema to prevent intubation in the emergency department: A retrospective cohort study. Emerg Med Int 2016:6091510, 2016.
19. Hassen GW, Kalantari H, Parraga M, et al. Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor-induced angioedema. J Emerg Med 44:764–772, 2013.
20. C1 Esterase Inhibitor (Human)." Pharmacy and Therapeutics 35.7 Section 2. 2–3, 2010.
21. Gelee B, Michel P, Haas R, and Boishardy F. Angiotensin-converting enzyme inhibitor-related angioedema: Emergency treatment with complement C1 inhibitor concentrate [in French with English abstract]. Rev Med Interne 29:516–519, 2008.
22. Lipski SM, Casimir G, Vanlommel M, et al. Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor (Berinert®): About one case and review of the therapeutic arsenal. Rev Med Interne 29:516–519, 2008.
23. Nielsen EW, and Gramstad S. Angioedema from angiotensin-converting enzyme inhibitor-related angio-oedema. BMJ Case Rep 2013:pii: bcr2013200652, 2013.
24. Javald N, Ahamlal J, Reuter PG, et al. Angioedema related to angiotensin-converting enzyme inhibitors: Attack severity, treatment, and hospital admission in a prospective multicenter study. Medicine (Baltimore) 94:e1939, 2015.